NSEGeneral Updates5 Jul 2026 · 5 Jul 2026, 02:10 pm
General Updates
Medplus Health Services Limited · MEDPLUS
✦ AI Summary▼ NegativeRegulatory
MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license of a store in Maharashtra, which may impact revenue.
Analysis Scores
Earnings Impact6/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk8/10
Balance Sheet Risk0/10
Liquidity Impact5/10
Market Sentiment2/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Attachments (1)
📄pdf
Download →
MEDPLUS_05072026141008_Intimation__3_.pdf
View document text
MedPlus Health Services Limited
July 05, 2026
The Listing Department The Listing Department
BSE Limited N ational Stock Exchange of India Limited
Phiroze Jeejebhoy Towers, Exchange Plaza, 5th Floor
Dalal Street, Fort, Plot No. C/1, G Block,
Mumbai – 400001 Bandra - Kurla Complex
BSE Scrip Code: 543427 Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS
Dear Sir/Madam,
Sub: Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015
We would like to inform you that Optival Health Solutions Private Limited, a subsidiary of the company, has
received one suspension order for a Drug License of a store situated in the state of Maharashtra:
Pursuant to SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD
POD2/I/3762/2026 dated January 30, 2026, the details of the matter are as follows:
Name(s) of the Authority Nature and details of Date of receipt of Details of the Impact on
the action(s) taken, direction or order, violation(s)/ financial
initiated or order(s) including any interim contravention(s) operation or
passed or interim orders, or committed or other activities of
any other alleged to be the listed entity,
communication from committed quantifiable in
the authority monetary terms
to the extent
possible
Asst. Commissioner & Suspension of Drug Order received on Under Rule 65 of Potential Revenue
Licensing authority, Food & License for five days 04.07.2026 Drugs and Cosmetics Loss of Rs 0.75
Drug Administrations, of store situated at Act, 1940 and Drugs lacs.
Nashik Maharashtra. Samta Nagar Nashik and Cosmetics Rules,
Maharashtra 1945
The same will be available on the website of the Company at www.medplusindia.com and also on the websites
of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com
respectively. Kindly take the same on records.
For MedPlus Health Services Limited
Gangadi Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097
040-6724 672
Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India
CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com